AZA decreased intracellular ROS levels and increased antioxidant capacity by upregulating Prdx2 and Prdx3, which maintained the intracellular redox balance and further suppressed AML in vitro and in vivo. The gene discussed is PRDX2; the disease is acute myeloid leukemia.